Amlodipine Besylate And Olmesartan Medoxomil Tablet, Film Coated
Product Images NDC 51407-857

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate And Olmesartan Medoxomil (NDC 51407-857). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Amlodipine Besylate (51407-857-30 test.jpg)

Amlodipine Besylate (51407-857-30 test.jpg)
This is a description of a medication called Amlodipine and Olmesartan Medoxomil Tablets, which comes in a pack of 30 tablets. Each tablet contains 5mg of amlodipine and 20mg of olmesartan. The manufacturer is GSMS, Incorporated based in Camarillo, CA, USA. The text also advises on proper storage conditions and keeping the medication out of reach of children. For detailed dosage instructions, refer to the accompanying Prescribing Information.*
FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure (sbp) < 140 Mmhg At Week 8 With Locf (Azor 01)

Figure 1: Probability Of Achieving Systolic Blood Pressure (sbp) < 140 Mmhg At Week 8 With Locf (Azor 01)
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure (dbp) < 90 Mmhg At Week 8 With Locf (Azor 02)

Figure 2: Probability Of Achieving Diastolic Blood Pressure (dbp) < 90 Mmhg At Week 8 With Locf (Azor 02)
Not available.*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure (sbp) < 130 Mmhg At Week 8 With Locf (Azor 03)

Figure 3: Probability Of Achieving Systolic Blood Pressure (sbp) < 130 Mmhg At Week 8 With Locf (Azor 03)
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure (dbp) < 80 Mmhg At Week 8 With Locf (Azor 04)

Figure 4: Probability Of Achieving Diastolic Blood Pressure (dbp) < 80 Mmhg At Week 8 With Locf (Azor 04)
FDA Label Image

The Structural Formula For Amlodipine Besylate Is Chemically Described As 3-ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, Monobenzene (Azor 05)

The Structural Formula For Amlodipine Besylate Is Chemically Described As 3-ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, Monobenzene (Azor 05)
FDA Label Image

The Structural Formula For Olmesartan Medoxomil Is Chemically Described As 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1h-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, C (Azor 06)

The Structural Formula For Olmesartan Medoxomil Is Chemically Described As 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1h-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, C (Azor 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.